Dexcom Inc is a leading company specializing in continuous glucose monitoring systems for individuals with diabetes. Their innovative technology enables users to track glucose levels in real time through a small sensor placed under the skin, eliminating the need for traditional fingerstick testing. The company's products empower patients and healthcare providers to make informed decisions regarding diabetes management, enhancing the quality of life for those living with the condition. By integrating advanced software and mobile applications, Dexcom's systems deliver essential insights and alerts, contributing to better health outcomes for users. Read More
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability.
But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
Let's have a look at what is happening on the US markets one hour before the close of the markets on Tuesday. Below you can find the top S&P500 gainers and losers in today's session.
A number of stocks jumped in the afternoon session after the major indices rebounded (Nasdaq +1.4%, S&P 500 +1.0%) on hopes the reported ceasefire between Israel and Iran will hold. This de-escalation in a volatile region helped to ease concerns about potential disruptions to global oil supplies, leading to a notable dip in crude oil prices.
DexCom, Inc., the global leader in glucose biosensing, today released its "Dexcom State of Type 2 Report: Access and Attitudes Across the United States" ahead of the 85th Scientific Sessions of the American Diabetes Association (ADA) in Chicago. The findings provide valuable insights into the perceptions around diabetes technology from more than 400 healthcare professionals and people with Type 2 diabetes across the United States.
Looking back on patient monitoring stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including DexCom (NASDAQ:DXCM) and its peers.
Johnson Fistel, PLLP, a leading stockholder rights law firm, has initiated an investigation into the board members and executive officers of DexCom, Inc. (NASDAQ: DXCM) for potential breaches of fiduciary duties and violations of the federal securities laws.
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns.
Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.
DEXCOM INC (NASDAQ:DXCM) shows strong growth fundamentals and a bullish technical setup, making it a stock worth watching for investors seeking growth opportunities.
DEXCOM INC (NASDAQ:DXCM) shows strong technicals and a high-quality setup, making it a potential breakout candidate. The stock's consolidation and bullish signals suggest a possible upward move.
While profitability is essential, it doesn’t guarantee long-term success.
Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".
Great things are happening to the stocks in this article.
They’re all outperforming the market over the last month because of positive catalysts such as a new product line, constructive news flow, or even a loyal Reddit fanbase.
Over the past six months, DexCom has been a great trade. While the S&P 500 was flat, the stock price has climbed by 15.6% to $87 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.
Medical device company DexCom (NASDAQ:DXCM) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 12.5% year on year to $1.04 billion. The company expects the full year’s revenue to be around $4.6 billion, close to analysts’ estimates. Its non-GAAP profit of $0.32 per share was in line with analysts’ consensus estimates.
